Advances in application of ctDNA in radiotherapy for non-small cell lung cancer

VernacularTitle:ctDNA在非小细胞肺癌放射治疗中的应用进展
Author: Yin YANG ¹ ; Tao ZHANG ; Nan BI
Author Information

1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科，北京　100021
Keywords: Circulating tumor DNA; Carcinoma, non-small-cell lung; Radiotherapy
From: Chinese Journal of Radiation Oncology 2022;31(9):838-842
CountryChina
Language:Chinese
Abstract: Circulating tumor DNA (ctDNA) has been the most common biomarker in liquid biopsy because of non-invasive detection and overcoming intratumor heterogeneity. Lung cancer remains the leading cause of cancer-related morbidity and mortality all over the world, with non-small cell lung cancer (NSCLC) constituting 85% of the total cases. Radiotherapy plays an important role in phase Ⅰ-Ⅳ NSCLC. It can not only kill tumor cells to eradicate cancer directly, but also increase the release of ctDNA indirectly, which improves the accuracy of liquid biopsy. As a result, ctDNA has the potential to be widely used in radiotherapy for NSCLC. In this review, research progress on ctDNA in the diagnosis, prognosis assessment, recurrence detection and response prediction in NSCLC patients treated with radiotherapy were summarized.